Oneness Biotech Co., Ltd. (LUX:ONES)

Market Cap	735.08M -3.1%
Revenue (ttm)	3.50M +9.5%
Net Income	-28.34M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	8.55
Day's Range	n/a
52-Week Range	8.00 - 12.90
Beta	n/a
RSI	60.53
Earnings Date	May 13, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, a wound care medical device. The company develops ON101, has completed clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase II a clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has received US FDA Phase II clinical trial for the treatment of rheumatoid arthritis and...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 43
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: ONES

Financial Performance

In 2025, Oneness Biotech's revenue was 129.12 million, an increase of 9.49% compared to the previous year's 117.93 million. Losses were -1.04 billion, -10.33% less than in 2024.

Financial numbers in TWD